ALTEOGEN Inc Asset Resilience Ratio
ALTEOGEN Inc asset resilience ratio. ALTEOGEN Inc (196170) has an Asset Resilience Ratio of 49.53% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 196170 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ALTEOGEN Inc (2014–2025)
Asset resilience ratio of ALTEOGEN Inc from 2014 to 2025. This chart shows how ALTEOGEN Inc's Asset Resilience Ratio has changed over time. Read 196170 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ALTEOGEN Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALTEOGEN Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩366.47 Billion | 49.53% |
| Total Liquid Assets | ₩366.47 Billion | 49.53% |
Asset Resilience Insights
- Very High Liquidity: ALTEOGEN Inc maintains exceptional liquid asset reserves at 49.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ALTEOGEN Inc Industry Peers by Asset Resilience Ratio
Compare ALTEOGEN Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
ALTEOGEN Inc Asset Resilience Ratio by Year (2014–2025)
ALTEOGEN Inc asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for ALTEOGEN Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 52.04% | ₩363.64 Billion ≈ $246.43 Million |
₩698.74 Billion ≈ $473.53 Million |
+6.75pp |
| 2024-12-31 | 45.29% | ₩185.25 Billion ≈ $125.54 Million |
₩409.01 Billion ≈ $277.18 Million |
+2.10pp |
| 2023-12-31 | 43.19% | ₩110.61 Billion ≈ $74.96 Million |
₩256.10 Billion ≈ $173.56 Million |
-8.76pp |
| 2022-12-31 | 51.95% | ₩127.54 Billion ≈ $86.43 Million |
₩245.49 Billion ≈ $166.37 Million |
-25.64pp |
| 2021-12-31 | 77.59% | ₩202.00 Billion ≈ $136.90 Million |
₩260.34 Billion ≈ $176.43 Million |
-6.36pp |
| 2020-12-31 | 83.95% | ₩133.66 Billion ≈ $90.58 Million |
₩159.21 Billion ≈ $107.89 Million |
+11.87pp |
| 2019-12-31 | 72.08% | ₩61.98 Billion ≈ $42.00 Million |
₩85.98 Billion ≈ $58.27 Million |
-0.09pp |
| 2018-12-31 | 72.17% | ₩51.52 Billion ≈ $34.91 Million |
₩71.38 Billion ≈ $48.37 Million |
-3.23pp |
| 2017-12-31 | 75.40% | ₩32.43 Billion ≈ $21.98 Million |
₩43.01 Billion ≈ $29.15 Million |
-2.43pp |
| 2016-12-31 | 77.82% | ₩37.32 Billion ≈ $25.29 Million |
₩47.95 Billion ≈ $32.49 Million |
+29.84pp |
| 2015-12-31 | 47.99% | ₩18.90 Billion ≈ $12.81 Million |
₩39.39 Billion ≈ $26.69 Million |
+9.39pp |
| 2014-12-31 | 38.60% | ₩14.65 Billion ≈ $9.93 Million |
₩37.96 Billion ≈ $25.72 Million |
-- |
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more